Leukaemia inhibitory factor in gastric cancer: friend or foe?

被引：8
|
作者：
Seeneevassen, Lornella [1 ]
Martin, Oceane C. B. [1 ]
Lehours, Philippe [1 ,2 ]
Dubus, Pierre [1 ,3 ]
Varon, Christine [1 ]
机构：
[1] Univ Bordeaux, INSERM, UMR 1053, Bordeaux Res Translat Oncol,BaRITOn, F-33076 Bordeaux, France
[2] CHU Bordeaux, Ctr Natl Reference Helicobacters & Campylobacters, F-33000 Bordeaux, France
[3] CHU Bordeaux, Inst Pathol & Tumor Biol, F-33000 Bordeaux, France
来源：
GASTRIC CANCER | 2022年 / 25卷 / 02期
关键词：
LIF; LIFR beta; Gastric cancer; JAK/STAT pathway; Hippo/YAP pathway; Cancer stem cells; Therapies; BREAST-CANCER; METASTASIS SUPPRESSOR; FACTOR-RECEPTOR; STEM-CELLS; EXPRESSION; LIFR; STAT3; TUMORIGENESIS; GROWTH; MODEL;
D O I：
10.1007/s10120-022-01278-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IL-6 family cytokine leukaemia inhibitory factor (LIF) study has deciphered a variety of effects, in physiology as well as pathology. Despite the sudden arousal in LIF interest in cancers, its study in the gastric cancer (GC) context has been put aside. Only few related studies can be found in literature, most of them investigating IL-6/STAT3 signalling in GC, and not the particular LIF/LIFR beta signalisation. LIF/LIFR has opposing effects depending on the signalling pathways involved. This review relates the pro- and anti-tumorigenic aspects of LIF/LIFR in GC, taking also into account facts from other types of cancer. A better understanding of these issues would undoubtedly help postulate interesting hypotheses and perspectives for future LIF/LIFR study and its use in GC therapies, where options tend to be limited in number and efficiency.
引用
收藏
页码：299 / 305
页数：7
相关论文
共 50 条
  • [31] Fibroblasts in cancer dormancy: foe or friend?
    Dai, Li
    Li, Mao
    Zhang, Wei-long
    Tang, Ya-Jie
    Tang, Ya-ling
    Liang, Xin-hua
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [32] Chemotherapy: Friend or foe to cancer vaccines?
    Emens, LA
    Machiels, JP
    Reilly, RT
    Jaffee, EM
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2001, 3 (01) : 77 - 84
  • [33] Hydrogen sulfide in cancer: Friend or foe?
    Wu, Dongdong
    Si, Weirong
    Wang, Mingjie
    Lv, Shuangyu
    Ji, Ailing
    Li, Yanzhang
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2015, 50 : 38 - 45
  • [34] Editorial: Anesthesia and cancer: Friend or foe?
    Bezu, Lucillia
    Diaz-Cambronero, Oscar
    Kepp, Oliver
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Sunitinib in breast cancer: Friend or foe
    Cardoso, Fatima
    Senkus-Konefka, Elzbieta
    BREAST, 2009, 18 (04): : 211 - 212
  • [36] Corticosteroids and Prostate Cancer: Friend or Foe?
    Geynisman, Daniel M.
    Szmulewitz, Russell Z.
    Plimack, Elizabeth R.
    EUROPEAN UROLOGY, 2015, 67 (05) : 874 - 875
  • [37] Interleukin 18: Friend or foe in cancer
    Palma, Giuseppe
    Barbieri, Antonio
    Bimonte, Sabrina
    Palla, Marco
    Zappavigna, Silvia
    Caraglia, Michele
    Ascierto, Paolo A.
    Ciliberto, Gennaro
    Arra, Claudio
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2013, 1836 (02): : 296 - 303
  • [38] Rho GTPases in cancer: friend or foe?
    Svensmark, Julius H.
    Brakebusch, Cord
    ONCOGENE, 2019, 38 (50) : 7447 - 7456
  • [39] Sulfonylurea derivatives and cancer, friend or foe?
    Hendriks, Anne M.
    Schrijnders, Dennis
    Kleefstra, Nanne
    de Vries, Elisabeth G. E.
    Bilo, Henk J. G.
    Jalving, Mathilde
    Landman, Gijs W. D.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 861
  • [40] Autophagy: Cancer's Friend or Foe?
    Bhutia, Sujit K.
    Mukhopadhyay, Subhadip
    Sinha, Niharika
    Das, Durgesh Nandini
    Panda, Prashanta Kumar
    Patra, Samir K.
    Maiti, Tapas K.
    Mandal, Mahitosh
    Dent, Paul
    Wang, Xiang-Yang
    Das, Swadesh K.
    Sarkar, Devanand
    Fisher, Paul B.
    ADVANCES IN CANCER RESEARCH, VOL 118, 2013, 118 : 61 - 95
12345